Last updated: October 12, 2022
Sponsor: Moscow Clinical Scientific Center
Overall Status: Active - Recruiting
Phase
N/A
Condition
Pancreatic Cancer
Breast Cancer
Digestive System Neoplasms
Treatment
N/AClinical Study ID
NCT05580887
Microbiome_BC&PnC
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- untreated early HR+ HER2- BC:
- planned neoadjuvant chemotherapy: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21days for 4 cycles
- TanyN1-3M0 Ki67>40% G3
- ECOG 0-1
- untreated early HR+ HER2- BC:
- TanyN0M0 Ki67<20% G1
- ECOG 0-1
- planned induction endocrine therapy (letrozole/anastrazole/tamoxifen)
- untreated locally-advanced and/or borderline resectable pancreas cancer:
- planned (neo)adjuvant chemotherapy: mFOLFIRINOX
- previous surgery ( only R0 resection) is allowed
- ECOG 0-1
- histology diagnosis verification
- Informed consent
- Eligible blood&fecal samples and tumor tissue for different time points
Exclusion
Exclusion Criteria:
- autoimmune disease
- active steroid therapy
- ECOG > 2
- any previous therapy for breast cancer
- metastatic cancer
- antibiotic use less than 28 days
- other tumor
Study Design
Total Participants: 35
Study Start date:
May 12, 2022
Estimated Completion Date:
August 31, 2025
Connect with a study center
Moscow Clinical Scientific Center named after AS Loginov
Moscow, Not Required Moscow
Russian FederationActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.